Seroglitazar tablets are a specialized pharmaceutical formulation designed for the effective management of metabolic and liver disorders, including Noncirrhotic Non-Alcoholic Steatohepatitis (NASH), type 2 diabetes mellitus, Non-alcoholic fatty liver disease (NAFLD), and diabetic dyslipidemia. This medication acts by modulating lipid and glucose metabolism, improving insulin sensitivity, and reducing hepatic fat accumulation to support liver health and glycemic control in patients. Seroglitazar tablets are prescribed to patients who require targeted therapeutic intervention for these conditions, emphasizing efficacy and safety based on clinical evidence.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Saroglitazar |
| Therapeutic Use | Treatment of NASH, Type 2 Diabetes Mellitus, NAFLD, and Diabetic Dyslipidemia |
| Dosage Form | Oral tablets |
| Mechanism of Action | PPAR alpha/gamma agonist to improve lipid and glucose metabolism |
| Indication | Noncirrhotic Non-Alcoholic Steatohepatitis and associated metabolic disorders |
| Administration Route | Oral |
| Patient Population | Adults with type 2 diabetes and liver-related metabolic conditions |
| Packaging | Blister packs (varies by manufacturer) |
| Regulatory Status | Prescription medication |
| Attributes | Description |
|---|---|
| Tablet Strength | Available in strengths typically 4 mg |
| Composition | Saroglitazar magnesium |
| Storage Conditions | Store below 30°C, protect from moisture and light |
| Shelf Life | Generally 2 years from manufacturing |
| Manufacturer Compliance | Manufactured as per GMP guidelines |
| Prescription Status | Prescription-only medicine |
| Pharmacological Classification | Antidiabetic and lipid-lowering agent |
| Country of Use | Primarily marketed and used in India |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Yes, Seroglitazar tablets are specifically indicated for managing NAFLD in patients with type 2 diabetes, improving both liver health and glycemic control.
Seroglitazar acts as a dual PPAR alpha/gamma agonist, which helps modulate lipid metabolism and insulin sensitivity, thereby addressing diabetic dyslipidemia effectively.
Seroglitazar tablets are indicated for Noncirrhotic Non-Alcoholic Steatohepatitis; use in cirrhotic patients should be carefully evaluated by a healthcare professional due to limited evidence.
Seroglitazar tablets should be stored below 30°C in a dry place, protected from moisture and direct light to maintain efficacy.
Yes, as a prescription-only medication, authorized documentation and prescriptions are mandatory for B2B procurement of Seroglitazar tablets.
Country Of Origin: India
Saroglitazar is used in the treatment of Noncirrhotic Non-Alcoholic Steatohepatitis, type 2 diabetes mellitus, Non-alcoholic fatty liver disease and diabetic dyslipidemia.
